<< Back To Search

Elimination of Minimal Residual Disease After Transplant

Notify the Multiple Myeloma Research Foundation You Are Interested In This Trial


Third Opinion Trial Synopsis:
This study is for patients with a type of cancer called multiple myeloma. The patients in the study have leftover cancer cells in their bone marrow after a certain type of treatment. The study will only have patients from one hospital and will test a new treatment.
*Third Opinion AI Generated Synopsis

Trial Summary
This is a single-center, single-arm, phase II study that will enroll multiple myeloma (MM) patients with persistent bone marrow minimal residual disease (MRD) post autologous stem cell transplant (ASCT) irrespective of the International Myeloma Working Group (IMWG) response.

Locations & Contact

Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.

Please share any additional considerations or concerns:
Example: Are you newly diagnosed? What treatments have you already been on?